Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
25
pubmed:dateCreated
2010-6-22
pubmed:abstractText
Undecaprenyl pyrophosphate synthase (UPPS) catalyzes the consecutive condensation of eight molecules of isopentenyl pyrophosphate (IPP) with farnesyl pyrophosphate (FPP) to generate the C(55) undecaprenyl pyrophosphate (UPP). It has been demonstrated that tetramic acids (TAs) are selective and potent inhibitors of UPPS, but the mode of inhibition was unclear. In this work, we used a fluorescent FPP probe to study possible TA binding at the FPP binding site. A photosensitive TA analogue was designed and synthesized for the study of the site of interaction of TA with UPPS using photo-cross-linking and mass spectrometry. The interaction of substrates with UPPS and with the UPPS.TA complex was investigated by protein fluorescence spectroscopy. Our results suggested that tetramic acid binds to UPPS at an allosteric site adjacent to the FPP binding site. TA binds to free UPPS enzyme but not to substrate-bound UPPS. Unlike Escherichia coli UPPS which follows an ordered substrate binding mechanism, Streptococcus pneumoniae UPPS appears to follow a random-sequential substrate binding mechanism. Only one substrate, FPP or IPP, is able to bind to the UPPS.TA complex, but the quaternary complex, UPPS.TA.FPP.IPP, cannot be formed. We propose that binding of TA to UPPS significantly alters the conformation of UPPS needed for proper substrate binding. As the result, substrate turnover is prevented, leading to the inhibition of UPPS catalytic activity. These probe compounds and biophysical assays also allowed us to quickly study the mode of inhibition of other UPPS inhibitors identified from a high-throughput screening and inhibitors produced from a medicinal chemistry program.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/20476728-10978182, http://linkedlifedata.com/resource/pubmed/commentcorrection/20476728-11287651, http://linkedlifedata.com/resource/pubmed/commentcorrection/20476728-11581264, http://linkedlifedata.com/resource/pubmed/commentcorrection/20476728-11744728, http://linkedlifedata.com/resource/pubmed/commentcorrection/20476728-12487597, http://linkedlifedata.com/resource/pubmed/commentcorrection/20476728-12756244, http://linkedlifedata.com/resource/pubmed/commentcorrection/20476728-15044730, http://linkedlifedata.com/resource/pubmed/commentcorrection/20476728-15788389, http://linkedlifedata.com/resource/pubmed/commentcorrection/20476728-18295483, http://linkedlifedata.com/resource/pubmed/commentcorrection/20476728-2991704, http://linkedlifedata.com/resource/pubmed/commentcorrection/20476728-4202581, http://linkedlifedata.com/resource/pubmed/commentcorrection/20476728-8180191, http://linkedlifedata.com/resource/pubmed/commentcorrection/20476728-9918669
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1520-4995
pubmed:author
pubmed:issnType
Electronic
pubmed:day
29
pubmed:volume
49
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5366-76
pubmed:dateRevised
2010-9-30
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Biophysical investigation of the mode of inhibition of tetramic acids, the allosteric inhibitors of undecaprenyl pyrophosphate synthase.
pubmed:affiliation
Infectious Diseases, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, USA.
pubmed:publicationType
Journal Article